Bayer AG (BAYGn.DE)
81.68EUR
6:04am EDT
€-0.69 (-0.84%)
€82.19
€82.93
€82.93
€81.49
515,139
2,272,443
€87.21
€56.00
BAYGn.DE
About
Overall
| Beta: | 0.77 |
| Market Cap (Mil.): | €68,115.69 |
| Shares Outstanding (Mil.): | 826.95 |
| Dividend: | 1.90 |
| Yield (%): | 2.31 |
Financials
| BAYGn.DE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 26.65 | 32.92 | 33.02 |
| EPS (TTM): | 3.09 | -- | -- |
| ROI: | 6.59 | 19.76 | 19.07 |
| ROE: | 12.89 | 20.57 | 20.00 |
BRIEF-Bayer's Nexavar submitted to EMA, FDA for thyroid cancer use
FRANKFURT, July 1 - Bayer AG : * Says sorafenib (nexavar) submitted to the ema and FDA for use in thyroid
Bayer cancer drug recommended in EU
LONDON, June xx - Experts at the European Medicines Agency have recommended approval of Bayer's drug Stivarga for the treatment of metastatic colorectal cancer.
Bayer rival Boehringer seeks wider use of anti-clotting pill
FRANKFURT - Boehringer Ingelheim has asked European regulators to approve a wider use of its anti-blood-clotting pill Pradaxa to include the treatment of deep vein thrombosis and pulmonary embolisms.
Europe shares dip as Chinese data hits miners
PARIS, June 10 - European stocks ended slightly lower on Monday as China's unexpectedly weak imports data prompted investors to dump cyclical miners and pick up defensive companies such as Deutsche Telekom and Bayer .
Bayer say VEGF Trap-Eye shows promise as mCNV treatment
FRANKFURT, June 6 - Bayer said on Thursday its drug VEGF Trap-Eye had demonstrated to improve visual acuity in a late-stage trial on patients suffering from myopic choroidal neovascularization (mCNV).
Bayer says 96.4 pct of Conceptus shares tendered
FRANKFURT, June 5 - German drugmaker Bayer said on Wednesday it had been offered 96.4 percent of the shares in Conceptus, the U.S. maker of female sterilisation devices it agreed to buy in April.
UK cost agency recommends Bayer, Regeneron eye drug
LONDON, May 31 - Britain's healthcare cost watchdog NICE is recommending a new eye drug from Bayer and Regeneron, after a price discount was offered for its use on the state health service.
France says will back down over Bayer acne pill
PARIS - France's health regulator said on Thursday it would comply with the European Commission if it ruled that Bayer acne pill Diane 35 and its generic versions were safe to use in some cases.
UPDATE 1-France says will back down over Bayer acne pill
PARIS, May 30 - France's health regulator said on Thursday it would comply with the European Commission if it ruled that Bayer acne pill Diane 35 and its generic versions were safe to use in some cases.
RPT-France says will comply with EU over Diane 35 pill
PARIS, May 30 - France's health regulator said on Thursday it would comply with the European Commission if it ruled that Bayer acne pill Diane 35 and its generic versions were safe to use in some cases.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Finlabo SIM Spa
|
$10.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Validea
|
$12.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
